DEVELOPING mPEG-PLA MICELLES FOR THE DELIVERY OF THE BIOACTIVE COMPOUND EXTRACTED FROM MARINE SPONGE DYSIDEA ROBUSTA AGAINST MULTIDRUG RESISTANT BACTERIA

• Grant number: 23/13928-3
• Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
• Start date: March 01, 2024
• End date: February 28, 2025
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Ana Claudia Muniz Renno
• Grantee: Cintia Cristina Santi Martignago
• Supervisor: Olivier Jordan
• Host Institution: Instituto de Saúde e Sociedade (ISS). Universidade Federal de São Paulo (UNIFESP). Campus Baixada Santista. Santos , SP, Brazil
• Institution abroad: Université de Genève, Switzerland
• Associated to the scholarship: 21/02974-9 - Interdisciplinar net for the development of biotechnological products from marine origin for use in human health: pathological complication of the osteoarticular system, BP.PD

Abstract

One of the most serious problems facing public health worldwide in recent years is antimicrobial resistance (AMR) to multiple drugs. This fact leads to an urgent need for studies aimed at discovering new substances with antimicrobial potential. Marine biodiversity has proven to be a substantial source of bioactive compounds with possible biotechnological applications for the treatment of various pathologies, including those of microbial origin. The aim of this research is to evaluate the efficiency of the bioactive compounds extracted from marine sponges incorporated into the mPEG-PLA micellar delivery system. Their antibacterial potential will be evaluated against multidrug-resistant bacteria such as Pseudomoas aeruginosa along with its wound healing. For this purpose, the crude extracts extracted from the marine sponges Dysidea robusta (ethanolic methanolic extracts 1:1 v/v and 100% methanolic) and their fractions (hexane, ethyl acetate and hydroalcoholic) will have their antimicrobial effects tested on the bacteria Pseudomonas aeruginosa. The extract that shows the greatest inhibition of Pseudomonas aeruginosa bacteria in preliminary tests will be incorporated into the mPEG-PLA micellar delivery system and will have its antimicrobial activity assessed by the following tests: determination of the minimum inhibitory concentration; minimum bactericidal concentration; time-kill kinetics test; serum stability test. Its biocompatibility will also be assessed by tests on fibroblast cell cultures, the hemolysis test and the WST-1 proliferation assay. It is believed that the incorporation of bioactive compounds extracted from marine sponges in the mPEG-PLA micellar delivery system will inhibit the bacterium Pseudomonas aeruginosa, which has the potential to be used for wound healing.